Corcept Therapeutics Inc Stock Price, News & Analysis

Corcept Therapeutics (NASDAQ: CORT) has scheduled its first quarter financial results announcement and corporate update for May 5, 2025. The company will host a conference call on the same day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Key Conference Call Details:

• Participants must pre-register through a provided link
• Each registrant will receive a unique dial-in number and access PIN
• One PIN allows access for one caller
• A listen-only webcast option is available
• Call replay will be accessible through Corcept's website under Investors / Events tab

The Redwood City-based pharmaceutical company is maintaining transparency with investors through this scheduled financial disclosure and stakeholder communication event.

Corcept Therapeutics (NASDAQ: CORT) has announced it will present late-breaking data from its pivotal Phase 3 ROSELLA trial at the 2025 ASCO Annual Meeting. The study evaluates relacorilant plus nab-paclitaxel combination therapy versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer.

The presentation is scheduled for Monday, June 2, 2025, from 8:00 AM to 11:00 AM CDT as part of the Gynecologic Cancer Oral Abstract Session (Abstract Number: LBA5507). The ROSELLA trial is being conducted through a global collaboration with multiple oncology research groups, including GOG Foundation, ENGOT, APGOT, LACOG, and ANZGOG.

Corcept Therapeutics (NASDAQ: CORT) has published findings from the prevalence phase of its CATALYST trial in Diabetes Care journal, revealing that 24 percent of patients with difficult-to-control type 2 diabetes showed signs of hypercortisolism (Cushing's syndrome).

The study, the largest of its kind, screened 1,057 patients across 36 U.S. sites. All participants had hemoglobin A1c levels exceeding 7.5 percent despite receiving multiple glucose-lowering therapies, including GLP-1 receptor agonists. The screening was conducted using a standardized 1-mg dexamethasone suppression test (DST).

Part two of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym® in patients with hypercortisolism and difficult-to-control type 2 diabetes, successfully met its primary endpoint of reduction in hemoglobin A1c. Complete results will be presented at the American Diabetes Association's 85th Scientific Sessions on June 23, 2025.

Corcept Therapeutics (NASDAQ: CORT) has launched BELLA, a new Phase 2 trial evaluating the combination of relacorilant with nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer. The single-arm, open-label trial aims to enroll 90 women across approximately 50 sites in North America, Europe, and Asia-Pacific.

The trial builds on the success of their pivotal Phase 3 ROSELLA trial, where the combination of relacorilant and nab-paclitaxel demonstrated improved progression-free and overall survival without increasing side effects. BELLA will investigate whether adding bevacizumab to this combination could provide an additional treatment option for patients.

Corcept Therapeutics (NASDAQ: CORT) announced positive results from its pivotal Phase 3 ROSELLA trial of relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer. The trial met its primary endpoint, demonstrating a 30% reduction in disease progression risk compared to nab-paclitaxel alone.

Key findings include:

• Median progression-free survival of 6.5 months vs 5.5 months for control group
• Median overall survival of 16.0 months vs 11.5 months for control group
• No new safety concerns identified

The trial enrolled 381 patients across multiple countries without requiring biomarker selection. Based on these results, Corcept plans to submit a New Drug Application (NDA) in Q3 and a Marketing Authorization Application (MAA) in Europe shortly after.

Corcept Therapeutics (NASDAQ: CORT) has launched the MOMENTUM clinical trial to investigate the prevalence of endogenous hypercortisolism (Cushing's syndrome) in patients with resistant hypertension. The study will enroll 1,000 patients across 45 U.S. sites.

The trial follows the successful CATALYST study, which found that one in four patients with difficult-to-control type 2 diabetes has hypercortisolism, with higher prevalence in patients requiring three or more hypertension medications. Patients will be identified as having hypercortisolism if they show dexamethasone suppression test values >1.8 µg/dL and dexamethasone levels >140 ng/dL.

Led by Dr. Deepak L. Bhatt, Director of Mount Sinai Fuster Heart Hospital, the study aims to better understand treatment opportunities for resistant hypertension patients. Results are expected by year-end.

Corcept Therapeutics (NASDAQ: CORT) announced that the FDA has filed its New Drug Application (NDA) for relacorilant, a selective cortisol modulator designed to treat patients with endogenous hypercortisolism (Cushing's syndrome). The FDA has set a PDUFA target action date of December 30, 2025.

The NDA submission is supported by positive results from multiple clinical trials, including the pivotal GRACE trial, Phase 3 GRADIENT trial, long-term extension trial, and a Phase 2 trial. Patients receiving relacorilant showed improvements in various hypercortisolism symptoms. The drug demonstrated favorable safety profiles with no instances of serious adverse events commonly associated with current treatments, such as drug-induced adrenal insufficiency, hypokalemia, or QT prolongation.

Corcept Therapeutics (NASDAQ: CORT) reported strong financial results for Q4 and full-year 2024. The company achieved revenue of $675.0 million in 2024, marking a 40% increase from 2023, with Q4 revenue at $181.9 million. Net income reached $141.2 million for 2024, up 33% year-over-year.

The company's cash position strengthened to $603.2 million as of December 31, 2024. Corcept provided 2025 revenue guidance of $900-950 million. Key developments include the submission of a New Drug Application (NDA) for relacorilant in hypercortisolism treatment, positive results from the GRACE and GRADIENT trials, and promising outcomes from the CATALYST study showing that 23.8% of patients with difficult-to-control type 2 diabetes have hypercortisolism.

Corcept Therapeutics (NASDAQ: CORT) has scheduled the announcement of its fourth quarter and full-year 2024 financial results for February 26, 2025. The company will provide a corporate update and host a conference call on the same day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Participants must pre-register for the conference call to receive their individual dial-in number and unique access PIN. A listen-only webcast option will also be available, and a replay of the call will be accessible through the Investors / Events section of Corcept.com.